Acadian Asset Management LLC Xencor Inc Transaction History

Acadian Asset Management LLC

  • $32.2 Billion
  • Q3 2024

A detailed history of Acadian Asset Management LLC transactions in Xencor Inc stock. As of the latest transaction made, Acadian Asset Management LLC holds 262 shares of XNCR stock, worth $6,212. This represents 0.0% of its overall portfolio holdings.

Number of Shares
262
Previous 4,712 94.44%
Holding current value
$6,212
Previous $89,000 94.38%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$15.7 - $21.65 $69,865 - $96,342
-4,450 Reduced 94.44%
262 $5,000
Q2 2024

Aug 06, 2024
SELL
$18.21 - $24.5 $84,895 - $114,219
-4,662 Reduced 49.73%
4,712 $89,000
Q1 2024

May 10, 2024
BUY
$18.65 - $26.52 $174,825 - $248,598
9,374 New
9,374 $206,000
Q2 2022

Aug 09, 2022
BUY
$19.74 - $29.01 $67,866 - $99,736
3,438 New
3,438 $94,000
Q4 2021

Feb 10, 2022
SELL
$33.67 - $43.44 $37,878 - $48,870
-1,125 Closed
0 $0
Q3 2021

Nov 12, 2021
BUY
$30.65 - $35.68 $15,600 - $18,161
509 Added 82.63%
1,125 $36,000
Q2 2021

Aug 11, 2021
SELL
$34.33 - $44.68 $48,302 - $62,864
-1,407 Reduced 69.55%
616 $21,000
Q4 2020

Feb 11, 2021
BUY
$36.63 - $47.63 $74,102 - $96,355
2,023 New
2,023 $88,000
Q3 2020

Nov 09, 2020
SELL
$30.09 - $43.02 $224,651 - $321,187
-7,466 Closed
0 $0
Q2 2020

Aug 12, 2020
SELL
$27.76 - $33.42 $19,237 - $23,160
-693 Reduced 8.49%
7,466 $242,000
Q1 2020

May 11, 2020
BUY
$20.69 - $37.79 $168,809 - $308,328
8,159 New
8,159 $245,000
Q4 2019

Feb 06, 2020
SELL
$32.75 - $41.43 $8,842 - $11,186
-270 Closed
0 $0
Q3 2019

Nov 07, 2019
BUY
$33.73 - $46.27 $9,107 - $12,492
270 New
270 $9,000

Others Institutions Holding XNCR

# of Institutions
215
Shares Held
71.5M
Call Options Held
2.5K
Put Options Held
7.9K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.42B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email